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ARTICLE
Dynamic molecular changes during the ﬁrst week
of human life follow a robust developmental
trajectory
Amy H. Lee 1, Casey P. Shannon 2, Nelly Amenyogbe3,25, Tue B. Bennike 4,5,6, Joann Diray-Arce5,6,
Olubukola T. Idoko7,8, Erin E. Gill1, Rym Ben-Othman9, William S. Pomat10, Simon D. van Haren5,6,
Kim-Anh Lê Cao 11, Momoudou Cox7, Alansana Darboe 7, Reza Falsaﬁ1, Davide Ferrari11,
Daniel J. Harbeson3, Daniel He 2, Cai Bing9, Samuel J. Hinshaw1,12, Jorjoh Ndure7, Jainaba Njie-Jobe7,
Matthew A. Pettengill5, Peter C. Richmond13,14, Rebecca Ford10, Gerard Saleu10, Geraldine Masiria10,
John Paul Matlam10, Wendy Kirarock10, Elishia Roberts7, Mehrnoush Malek15, Guzmán Sanchez-Schmitz5,6,
Amrit Singh 2,16, Asimenia Angelidou5,6,17, Kinga K. Smolen5,6, The EPIC Consortium#, Ryan R. Brinkman15,18,
Al Ozonoff5,6,19, Robert E.W. Hancock 1, Anita H.J. van den Biggelaar14, Hanno Steen 4,5,7,
Scott J. Tebbutt 2,20,21, Beate Kampmann7,22, Ofer Levy 5,6,23 & Tobias R. Kollmann 3,9,25
Systems biology can unravel complex biology but has not been extensively applied to human
newborns, a group highly vulnerable to a wide range of diseases. We optimized methods to
extract transcriptomic, proteomic, metabolomic, cytokine/chemokine, and single cell immune
phenotyping data from <1 ml of blood, a volume readily obtained from newborns. Indexing to
baseline and applying innovative integrative computational methods reveals dramatic chan-
ges along a remarkably stable developmental trajectory over the ﬁrst week of life. This is
most evident in changes of interferon and complement pathways, as well as neutrophil-
associated signaling. Validated across two independent cohorts of newborns from West
Africa and Australasia, a robust and common trajectory emerges, suggesting a purposeful
rather than random developmental path. Systems biology and innovative data integration can
provide fresh insights into the molecular ontogeny of the ﬁrst week of life, a dynamic
developmental phase that is key for health and disease.
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The ﬁrst week of life is characterized by heightened sus-ceptibility to infections and is increasingly recognized as amajor determinant of overall health for the entire human
lifespan1,2. Knowledge of the molecular drivers involved in these
processes in newborns (deﬁned as those <28 days of life) is
fragmentary. Systems biology approaches, employing high-
dimensional molecular and cellular measurements (henceforth
referred to as OMICs), along with unbiased analytic approaches,
have increased our understanding of basal and altered molecular
states in adults3 and recently in newborns and infants after the
ﬁrst week of life4,5, but such approaches have not been applied
systematically to characterize molecular ontogeny over the most
critical period, i.e. the ﬁrst week of life1. This is likely due to the
analytical challenges posed by the limited amount of biosample
that can be obtained6–8 and the many rapid physiological changes
around birth1. The resulting variance in biological measurements
has been thought to necessitate a large participant sample size,
which would increase complexity and cost9.
To overcome these hurdles, we developed a robust experi-
mental and analytical approach feasible with <1 ml of newborn
blood. Our data represent the most comprehensive systems
biology study yet performed during the ﬁrst week of human life.
Despite substantial between-subject variation, normalizing
(indexing) all samples from a given newborn enabled identiﬁca-
tion of consistent and robust changes over the ﬁrst week of life
across the entire cohort. Furthermore, data integration using
independent strategies not only validated signatures across
methodologically- and biologically-distinct datasets, but also
provided novel ﬁndings. The major observations derived from a
cohort from West Africa (The Gambia) were validated for an
Australasian (Papua New Guinea) cohort. Our results highlight
that, contrary to the relatively steady-state biology observed in
healthy adults7,10, the ﬁrst week of human life is highly dynamic.
Nevertheless, despite the substantial variability between partici-
pants and these dramatic changes, ontogeny followed a robust
trajectory common to newborns from very different areas of the
world.
Results
Blood processing. One of the objectives of this project was to
develop a robust standard operating protocol (SOP) to enable
extraction and analysis of data using systems biology (big data)
approaches from small blood sample volumes that can readily be
obtained for research purposes from newborns within the ﬁrst
week of life (Fig. 1, see also Protocol). Our experimental SOP
utilized important sample-sparing modiﬁcations whereby we
obtained samples for immune phenotyping, transcriptomic,
proteomic, and metabolomic analysis from <1 ml of blood (see
also Supplementary Methods)11. We proﬁled the peripheral blood
of each participant twice over their ﬁrst week of life, i.e. at Day of
Life (DOL) 0 (baseline) and additionally at either DOL1, 3, or 7,
and sought to identify variables that differed between the baseline
and later time points across all participants. This required
indexing either by employing paired statistical tests for univariate
analyses or calculating fold changes relative to the DOL0 sample
for multivariate analyses, as described in online Methods. The
number of samples used in each OMIC platform as well as the
analysis stage are shown in Supplementary Table 1 and Supple-
mentary Figure 9.
Immune phenotyping across ﬁrst week of life. Determining the
cellular composition of biological samples is important in systems
biology, as relative and absolute cell numbers predict endpoints of
interest with high accuracy, e.g. vaccine responses12, and enable
deconvolution of OMICs data9,13. Analysis of our predeﬁned
targeted cell populations revealed substantial between-subject
variability in peripheral blood samples obtained over the ﬁrst
week of life (Fig. 2, Supplementary Figure 2, Supplementary
Note 1). However, consistent within-subject changes over the ﬁrst
week of life amongst the entire cohort of 30 Gambian newborns
emerged when samples were indexed as displayed by principal
component analysis (PCA). Univariate analysis identiﬁed the
following discriminating cellular features over the ﬁrst week of
life: basophils, plasmacytoid dendritic cells (DC), natural killer
cells, and neutrophils decreased; in contrast, myeloid DCs
increased after DOL0, while many other cell types remained
stable. We also detected dramatic but consistent changes in
soluble immune markers including plasma cytokines and che-
mokines over the ﬁrst week of life (Fig. 2). Based on the relevant
univariate analysis, we found that plasma concentrations of C−X
−C motif chemokine 10 (CXCL10), interleukin (IL)-17A,
macrophage-derived chemokine (MDC), and interferon (IFN)γ
increased, while IL-10, Chemokine C−C motif ligand (CCL) 5,
granulocyte colony stimulating factor 2 (GCSF), and IL-6
decreased with age over the ﬁrst week of life; many other solu-
ble immune markers remained unchanged.
Transcriptomic analysis across ﬁrst week of life. Modern sys-
tems biology studies employ gene expression analysis by RNA-
Seq7,14. We found that ≥500 μl of adult blood was required to
consistently obtain sufﬁcient high-quality RNA, but <100 μl of
newborn blood sufﬁced (Supplementary Figure 3). This likely
reﬂected the relatively high content of white blood cells (WBC)
and nucleated red blood cells in newborn blood, which contain
abundant globin mRNA15. The higher yield and quality of total
RNA extracted from newborn vs. adult whole blood was con-
ﬁrmed across different RNA extraction platforms (RNALater and
PAXGene; both of which yielded similar results) with the former
chosen for subsequent studies (Supplementary Methods).
As with the immune phenotyping data, there was substantial
between-subject variability in our RNA-Seq data from peripheral
blood samples obtained over the ﬁrst week of life. This was
resolved by indexing each participant to their own DOL0 sample,
revealing dramatic yet consistent developmental signals that
related to age (i.e. ontogeny) to emerge across the entire cohort.
We were concerned that the above-mentioned changes in cell
composition could provide a basis for the observed differentially
expressed (DE) genes, but the inclusion of cell composition data
in our model did not affect our results (see Methods (Online) and
Supplementary Figure 3 for details) demonstrating that the whole
blood transcriptomic signals driving the developmental trajectory
observed were not merely a consequence of changes in the
underlying cellular composition across DOL.
In comparing DOL1 vs. DOL0, there were few (12) identiﬁed
DE genes; however, dramatic developmental changes emerged
when comparing later days of life to DOL0 (Fig. 3a). Speciﬁcally,
for DOL3 vs. DOL0 we detected 1125 DE genes, while on DOL7
vs. DOL0, there were 1864 DE genes. All DE genes, pathway
enrichment and statistics are listed in Supplementary Data 5 and
Supplementary Methods. In particular, genes with decreased
expression across the ﬁrst week of life are involved in cellular
responses to stress, detoxiﬁcation of reactive oxygen, as well as
heme biosynthesis and iron uptake. Conversely genes involved in
interferon signaling, Toll-like-receptor (TLR), negative regulation
of Retinoic Acid Inducible Gene I (RIG-I) and complement
activation were upregulated over the ﬁrst week of life.
Proteomic analysis across ﬁrst week of life. A total of 684 dif-
ferent proteins were identiﬁed across peripheral blood plasma
samples (false discovery rate (FDR) < 1%) (Supplementary
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Figure 4). Of these, 199 proteins met our criteria, including
detection of at least two unique peptides per protein, for further
detailed quantiﬁcation. Substantial between-subject variability
was also noted in the plasma proteomic analysis, but again
indexing each participant to their baseline enhanced signature
detection. This approach indicated a common developmental
trajectory over the ﬁrst week of life, with differences in plasma
protein composition compared to DOL0 increasing with
increasing age (Fig. 3b). Differentially abundant plasma proteins
and their respective pathways are listed in Supplementary Data 6
and Supplementary Methods. At DOL3 vs. DOL0, three pathways
were upregulated that center around the complement cascade; at
DOL7 vs. DOL0, ﬁve additional pathways were upregulated
including scavenging heme from plasma and signaling to RAS.
Metabolomic analysis across ﬁrst week of life. While initial
analysis revealed substantial between-subject variation, indexing
metabolomic data to DOL0 also revealed a steady but dramatic
developmental trajectory in the plasma metabolome (Supple-
mentary Figure 5). Few differences in plasma metabolites were
identiﬁed comparing DOL1 vs. DOL0, but increasing differences
were noted when contrasting DOL3 or DOL7 vs. DOL0 (Fig. 3c).
Interestingly, metabolomic differences detected across age
involved pathways related to plasma steroids and carbohydrate
metabolites, possibly reﬂecting neurodevelopment, rapid cell
proliferation and increased uptake of nutrients in newborns
(Supplementary Data 7 and Supplementary Methods)16.
Data integration. Each methodologically- and biologically dis-
tinct data type that we examined revealed substantial changes
over the ﬁrst week of life. We thus sought to determine if the
observed changes were related to one another across data types,
validating consistent age-dependent changes in functional path-
ways. To minimize the limitations inherent in any single analy-
tical approach, and to detect the most robust signatures, data
integration was addressed using three independent strategies. To
this end, we employed a novel function-based strategy based on
biologically known Molecular Interaction Networks using Net-
workAnalyst17; an unbiased data-driven multivariate matrix fac-
torization approach using DIABLO (Data Integration Analysis
for Biomarker discovery using Latent cOmponents)18–20; and the
multiscale, multifactorial response network (MMRN) approach
that estimates correlations across data types7,21.
NetworkAnalyst enables the creation of networks based on a
framework of known protein−protein interactions (PPI) captured
in publicly curated databases (speciﬁcally InnateDB/IMeX)22.
Minimum-connected networks were constructed from seed nodes
(i.e. from genes or proteins that changed with age in our dataset),
DOL 0 DOL 1 DOL 3 DOL 7
30
60
1 ml blood in
heparin
0.3 ml
Plasma
0.4 ml
PLAS 1
PLAS 2
PLAS 3
FLOW 1
FLOW 2
FLOW 3
FLOW 4
Plasma proteomics
and metabolomics
Single cell
immunophenotyping
0.4 ml Other
CELLS0.8 ml blood in
heparin
Transcriptomics Blood cells/RPMI(0.8 ml)
0.2 ml blood in
RNA later
10 10 10
Fig. 1 Sample processing overview. Thirty newborns were recruited in The Gambia, with each newborn providing a peripheral blood sample on DOL0 and
subsets of ten newborns each providing a second peripheral blood sample at either DOL1, 3 or 7, resulting in a total of 60 blood samples. Newborn
peripheral venous blood was drawn directly into heparinized collection tubes. Aliquots (200 μl) were removed for transcriptomic analysis. Plasma was then
harvested from the remaining whole blood after a spin, and cryopreserved for cytokine, proteomic and metabolomic analyses. The remaining cellular
fraction was diluted with phosphate-buffered saline (PBS) to replace the volume of plasma removed, and 100 μl aliquots from this mixture were processed
for single-cell immunophenotyping by ﬂow cytometry. With a starting volume of 1 ml, this standard operating protocol still left the cellular fraction
contained in 400 µl of starting blood volume that could be used for other analyses. DOL: day of life
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as well as ﬁrst-order interactors that served to connect the seed
nodes with each other. To incorporate metabolomics data,
synthetic and degradative metabolic enzymes that would
determine the levels of differentially detected metabolites were
used as seed nodes in network construction. Overall metabo-
lomics, proteomics and transcriptomics data ﬁt well into a single
functional network (Fig. 4), indicating that these techniques
reported on different facets of the same biological processes. This
PPI-based integration strategy recapitulated many key ﬁndings
that had been identiﬁed for each of the individual data types,
conﬁrming our expectation that many but not all ﬁndings would
be validated across different OMICS datasets (Supplementary
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Data 8). For example, integrating transcriptomic with proteomic
data afﬁrmed the increase in type 1 IFN-related functions and the
regulation of complement cascades over the ﬁrst week of life. This
integration also revealed new biological insights not found in any
single-data domain analysis, such as changes in cellular replica-
tion machinery, creatine metabolism (DOL3), ﬁbrin clotting
cascade and signals of increasing adaptive immune and phago-
some activity (DOL7).
DIABLO is a multivariate approach to address two of the major
concerns faced when integrating multicomponent datasets, namely
the complexity of the data, particularly with few samples, each
with many observations, and the heterogeneous nature of data
measured on different scales and technological platforms18–20.
DIABLO constructs components (linear combinations of the
original data—cells, cytokines, transcripts, proteins, metabolites)
that are maximally correlated across any number of input data
types with a speciﬁed outcome variable (in this case, DOL), while
simultaneously performing marker selection23 to identify a
minimal subset of markers associated with this outcome
(Supplementary Methods). We created matrices from our ﬁve
Fig. 2 Indexing cellular and soluble immune markers revealed developmental progression over the ﬁrst week of life. a, b Principal component analysis was
used to plot cellular composition (a) and plasma cytokines/chemokine concentration (b) for each sample; this highlighted the substantial variability
between participants and lack of deﬁned clustering by DOL due to higher inﬂuence of individual variance over ontogeny. c, d Accounting for repeat
measures from the same individual across different sampling days compared to DOL0 (indexing to DOL0) revealed sample clustering by DOL between
samples. e, f Normalized cell counts showing developmental trajectories for cell populations that signiﬁcantly changed (e) or did not change (f) over the
ﬁrst week of life. g, h Normalized plasma cytokine/chemokine concentrations showing developmental trajectories for cytokines/chemokines that
signiﬁcantly changed (g) or did not change (h) over the ﬁrst week of life. Boxplots display medians with lower and upper hinges representing ﬁrst and third
quartiles. Whiskers reach the highest and lowest values, no more than 1.5× interquartile range from the hinge. ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01,
*p≤ 0.05, ns p > 0.05, Kruskal−Wallis test, Benjamini−Hochberg adjusted p values. DOL: day of life
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Fig. 3 Transcriptomic, proteomic, and metabolomic analyses identiﬁed a robust trajectory of differentially expressed genes, proteins, and metabolites over
the ﬁrst week of life. a Up- and downregulated differentially expressed genes were plotted by DOL (vs. DOL0) and numbers of genes are listed above each
point except for downregulated genes at DOL1 vs. DOL0, where the number was zero. b, c Up- and downregulated differentially expressed proteins and
metabolites, respectively, plotted by DOL compared to DOL0, with numbers of differentially expressed proteins or metabolites listed above each point.
d Zero-order interaction networks for genes differentially expressed at DOL3 vs. DOL0 and DOL7 vs. DOL0. Within networks, upregulated nodes are
displayed in red and downregulated nodes in blue. DOL: day of life
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data types as an input to DIABLO to identify major ontogeny-
related markers (Fig. 5, Supplementary Figure 6 and Supplemen-
tary Data 9). The resulting model discriminated well between
DOLs, outperforming nonintegrative approaches (Supplementary
Figure 6), with component one of the model separating birth
(DOL0) from all other time points, while component two
separated DOL1, 3, and 7 from each other. We next investigated
the relationship between features selected by DIABLO across data
types and visualized the selected features in an integrative
network (Supplementary Methods). We compared this integrative
network (Fig. 5a, b) to one derived from features identiﬁed using
an alternative, nonintegrative sparse discriminant analysis
approach (Supplementary Methods). The integrative network
was more densely connected (global clustering coefﬁcient= 0.91
vs. 0.68) and composed of few, more tightly connected modules
(network modularity= 0.26 vs. 0.09), indicating that DIABLO
selected features that were discriminant and well correlated
across data types, while the nonintegrative approach favored
markers that were not well correlated across data types. The
two components of the DIABLO model were composed
of distinct sets of features (Fig. 5d, blue bars), representing
distinct biology (Fig. 5e, blue bars). The ﬁrst component
reﬂecting DOL0 was composed of markers consistent with
interferon and cytokine signaling, among other immune biology
(Fig. 5a, Supplementary Methods). The second component,
reﬂecting progression across DOL1–7 had a distinct granulo-
cyte-ﬂavor, as well as a focus on cytokine signaling in the immune
system and cellular response to latent infections (Fig. 5a,
Supplementary Methods).
MMRNs are a recently published framework for data
integration7. Using MMRN, we found that associations between
data types were strongest at DOL1 and decreased across the ﬁrst
week of life (Supplementary Figure 7), conﬁrming the already
noted robust trajectory of development. Most of the signiﬁcantly
correlated clusters were transcriptomic (16/21), but we also
identiﬁed metabolomic (1/21) and ﬂow cytometry-derived (4/21)
clusters associated with DOL (Supplementary Data 10). The
stable clusters most signiﬁcantly associated with DOL were
composed of blood transcriptomic modules (BTMs) related to
DCs and monocytes including cytokine receptors CCR1 and
CCR7, TLR and inﬂammatory signaling, heme biosynthesis,
various B-cell subpopulations, as well as metabolic pathways such
as purine metabolism7.
Meta-integration. To assess the similarities across methodologi-
cally distinct integration methods, we analyzed the list of nodes
associated with DOLs for each integration approach. We then
carried out pathway enrichment to determine which biological
processes were identiﬁed by each method (Supplementary
Data 11 and 12). The selected nodes for Molecular Interaction
Networks (NetworkAnalyst) were those nodes of minimum-
connected networks when differentially abundant features for
DOL3 vs. DOL0 and DOL7 vs. DOL0 were used as seed nodes
(3195 features). For DIABLO, a ﬁrst-order molecular interaction
network was constructed using as seed nodes the markers derived
from model components 1 and 2 (428 features). For MMRN,
selected nodes were those that comprised the stable network
shown in Supplementary Figure 7 (675 features).
We observed limited overlap at the individual marker level.
However, assessing the above networks using the Reactome
pathway annotation system (2208 pathways) revealed that 635,
308 and 84 pathways were signiﬁcantly over-represented in the
NetworkAnalyst, DIABLO and MMRN feature lists, respectively
(paired t test DOL0 vs. DOL1, 3, or 7, Benjamini−Hochberg
corrected FDR ≤ 0.05; Supplementary Data 11). Importantly, 249
and 25 pathways were identiﬁed by NetworkAnalyst and either
DIABLO or MMRN, respectively, and 34 pathways were
identiﬁed by all three approaches, demonstrating a strong
congruence between the outputs and conclusions derived from
different analytical/OMICS platforms (Fig. 6a). This degree of
overlap was unlikely to occur by chance alone as determined by
bootstrapping (p value < 0.001; Supplementary Figure 8 and
Supplementary Methods). The speciﬁc pathways identiﬁed by this
meta-integration as driving molecular ontogeny over the ﬁrst
week of life were related to interferon signaling, complement
cascade and granulocyte function (Supplementary Data 12).
Given the striking convergence observed, we next assessed
relevant functional interactions between the pathways identiﬁed
in silico via our meta-integration. To this end, we used
NetworkAnalyst and found that selected common features ﬁtted
into minimum-connected networks of experimentally validated
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interactions (Supplementary Figure 8), implying functional
interconnections. This validation conﬁrmed that our meta-
integration approach identiﬁed functionally important biological
interactions central to neonatal ontogeny.
Cross-cohort validation. To validate the generalizability of these
integrative models based on data from Gambian (West Africa)
newborns, we recruited and characterized an independent new-
born cohort (30 participants) from a different region of the world
(Papua New Guinea (PNG), Australasia). This validation cohort
was processed according to the same methods as described above
(Fig. 1 and Supplementary Figure 9). The outputs for the PNG
data demonstrated the same basic trajectory as a function of DOL
and showed considerable overlap (e.g. in transcriptomics p <
10–138 for the Jaccard index/similarity for DOL3 vs. DOL0 and
DOL7 vs. DOL0 in the two cohorts). Overall, integrative multi-
variate modeling using DIABLO predicted the correct DOL well
for these independent cohorts (Fig. 6, Supplementary Figure 10).
To quantify the predictive performance of this model, we used the
area under the receiver operator characteristics curve (AUROC).
Overall predictive accuracy was very high for the transcriptomic
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data, with samples from DOL0 and DOL7 separating from all
other DOL and near-perfect AUC values (0.98 and 0.95, respec-
tively) while samples from DOL3 or DOL1 were more challenging
to classify (0.84 and 0.60, respectively). A functional zero-order
network that included key DIABLO-selected features that predict
the DOL highlighted in the PNG cohort pathways related to
interferon signaling, complement and neutrophil activ-
ity (Fig. 6d), as was observed for the Gambian cohort. Thus, we
were able to validate the complex Gambian dataset in an inde-
pendent and distinct population of newborns.
Discussion
We present a holistic suite of complementary methods that
addressed key hurdles of applying systems biology to the ﬁrst
week of human life by: (i) overcoming limitations in sample
volume via an efﬁcient, ﬁeld-compatible, sample-sparing SOP to
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process peripheral whole blood; (ii) determining the develop-
mental trajectories from each participant’s own baseline (index-
ing), and (iii) reducing the complexity of the dataset by
integrating biologically distinct data types generated via a variety
of methods (multi-OMICS integration), which enabled validation
of signatures of important pathways. The major conclusions were
validated in two independent and distinct cohorts of newborns.
This approach revealed a dramatic molecular ontogeny evolving
over the ﬁrst week of human life along a common and robust
developmental trajectory. Our observation indicates that devel-
opment over the ﬁrst week of human life is not immature and
random but follows a precise and age-speciﬁc path.
This approach was afﬁrmed by its ability to identify known
changes in early life, including those related to the composition of
hemoglobin mRNA, increases in complement protein C9 and
reductions in plasma steroid metabolites such as pregnanolone/
allopregnanolone sulfate and pregnanediol-3-glucoronide24
(Supplementary Figure 5) that are important for neonatal neu-
rodevelopment16, supporting the validity of our ﬁndings. More-
over, our approach also identiﬁed pathways never previously
identiﬁed as relevant to ontogeny. For example, many pathways
upregulated across the ﬁrst week of life consistently identiﬁed by
all of our analytical strategies are relevant for host defense but
have not before been identiﬁed as central to early human devel-
opment. These pathways included interleukin 1 signaling, Toll-
like receptor signaling, NOTCH signaling, the DHX RNA helicase
pathway leading to interferon signaling, as well as regulators of
the complement cascade1. Upregulation of these pathways across
the ﬁrst week of life may represent a heightened defense function
for vulnerable newborns who are especially dependent on innate
immunity1. Data integration also identiﬁed novel and surprising
but biologically plausible ﬁndings regarding ontogeny. For
example, prostaglandin-endoperoxide synthase 2 (PTGS2 or
PGHS2 or COX-2) appeared as centrally important in all of our
integrative networks, but not in any of the single OMICS data
types analyzed individually. PTGS2 is expressed abundantly in
hematopoietic progenitors25 and is clinically relevant during
premature labor and in necrotizing enterocolitis26,27. Taken
together, our ﬁndings outlined a developmental process that can
serve as a reference, akin to the stable steady state in adults7,10,12.
Deviations from this developmental trajectory could potentially
identify at-risk individuals prior to disease onset, indicate
potential beneﬁt for interventions, or guide the re-establishment
of homeostasis once derailed.
Multi-OMICS integration poses an exceptional problem due to
the increase in complexity (p data points) relative to the typically
achievable sample size (n samples). Here we addressed this p≫n
problem by reducing data complexity via selection of a subset of
variables (MMRN, DIABLO)28, or, for the NetworkAnalyst
approach, imposing functionally relevant molecular interaction
information21. Furthermore, we applied integrative methods
focused on extracting aggregated information from each dataset
independently of each other, providing high conﬁdence in results
that converged on the same set of key molecular features. Overall
our approach conﬁrmed that integrating across multiple different
biological data types dramatically increased robust biological
insights. Technical and analytical improvements, such as imple-
mentation of our enhanced plasma proteomics workﬂow29, will
further increase our understanding of the dynamic molecular
changes.
Our integrative approach identiﬁed several key pathways as
central to ontogeny. These pathways centered around and
interconnected interferon signaling, the complement cascade, and
neutrophil activity. Each of these have previously been recognized
individually as possible contributors to the increase in newborn
susceptibility to infection1, but their age-dependent change had
not previously been known to be centrally important to ontogeny
over the ﬁrst week of human life. Importantly, the three key
pathways constituting the core of an early life developmental
trajectory were readily validated across two independent cohorts
of newborns from very different populations, further conﬁrming
that the observed early life trajectory is common and predictable
and thus could serve as a baseline reference. The ﬁnding of a
stable trajectory in the ﬁrst week of life has profound implica-
tions: the newborn immune system is still often viewed as
immature, which implies a stochastic, unregulated state. How-
ever, the existence of the developmental trajectory we discovered
as shared by newborns across very different populations in the
world strongly argues that early life immune ontogeny is not
random but follows a precise and thus possibly purposeful path1.
Alternatively, the developmental trajectory we observed over the
ﬁrst week of life could be the result of a limited range of response
possibilities in early life, as recently espoused in the hypothesis of
stereotypic immune system development4. Differentiating
between these possibilities (a proactive, purposeful path vs. a
reactive, restricted response) will be critical for understanding
normal development as well as diagnosing, preventing and
treating disease in early life1.
In summary, our study presents an integrative analysis across the
broadest range of multivariate datasets published to date covering
the ﬁrst week of human life. Our integration over time (indexing
data longitudinally for each newborn) and biological space (multi-
OMICS integration) enabled exploration of the dynamic molecular
and cellular developmental characteristics of early life. In parallel,
Fig. 6 Independent validation and data meta-integration of the robust developmental trajectory during the ﬁrst week of life. Generalizability of the
multivariate integrative model (DIABLO) depicted in Fig. 5 based on data from Gambian newborns was evaluated by assessing its ability to classify DOL
from OMICs proﬁles in a new set of validation samples collected from newborns from a second site (Papua New Guinea (PNG)). a Pathway enrichments of
Molecular Interaction Networks Integration, DIABLO and MMRN identiﬁed congruent functional pathways of the ﬁrst week of life. b The dashed line
corresponds to the 95% conﬁdence level ellipses for the scores obtained from the Gambia training data. Samples from the PNG site generally resided
within the correct ellipse, demonstrating good agreement between actual DOL and DOL as predicted by the model. Similar ﬁgures were generated for other
OMICs data (Supplementary Figure 10). c This agreement was quantiﬁed using area under the receiver operator characteristics curve (AUROC) analysis
comparing DOL0 (red), 1 (blue), 3 (green), and 7 (purple) individually vs. all other DOLs combined. d shows zero-order interaction networks for DOL7 vs.
DOL0 containing nodes for transcriptome (blue), proteome (green), metabolome (red), and DIABLO-selected features (purple). Genes involved in the
interferon and complement pathways and neutrophil degranulation are highlighted by the orange boxes. e−g Relative abundance of a selected subset of
markers identiﬁed by DIABLO are shown for each DOL for both the Gambian cohort, on which the model was trained, and the validation cohort from PNG.
The cells (ﬂow cytometry; FC), plasma cytokines (Luminex assay; CYT) and plasma proteins (mass-spectrometry proteomics; PROT), transcripts (RNA-
Seq; RNA), and metabolites (mass-spectrometry metabolomics; META) identiﬁed by DIABLO were associated with interferon signaling (e), neutrophil
recruitment and activation (f), and complement pathways (g). The differences observed between DOLs in the Gambia cohort were generally replicated in
the PNG cohort. Boxplots display medians with lower and upper hinges representing ﬁrst and third quartiles; whiskers reach the highest and lowest values
no more than 1.5× interquartile range from the hinge ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05, ns p > 0.05, by ANOVA. DIABLO: Data Integration
Analysis for Biomarker discovery using Latent cOmponents, DOL: day of life, MMRN: multiscale, multifactorial response network
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we identiﬁed signals of potential physiological importance using a
practical sample size. Coupled with our ﬁeld-tested SOP for sample-
sparing preanalytical processing, this strategy overcomes key chal-
lenges in applying systems biology to neonates. Our data revealed a
compelling biological narrative, where out of the apparently noisy
age-dependent changes across the ﬁrst week of life, a consistent
developmental trajectory emerged. The interactive contributors to
this trajectory relate to cell autonomous as well as innate immune
functions, such as interferon-driven signaling, complement cas-
cades, and neutrophil function1. Our approach and the resulting
observations will serve as a crucial backdrop for future studies that
characterize the impact of a broad array of factors, including
genetics, epigenetics, maternal inﬂuences, microbiota, diet, and
disease, as well as chemical and biomedical interventions such as
antibiotics and vaccination.
Methods
Overview. A workﬂow diagram is provided in Supplementary Figure 1 that out-
lines the precise sample processing steps as well as the statistical and bioinformatic
analyses steps applied to the data.
Peripheral blood processing. Thirty healthy, term newborns were enrolled at each
of the Medical Research Council (MRC) Unit The Gambia and at the Institute for
Medical Research (IMR) in Goroka, Papua New Guinea in accordance with a local
Ethics Committee-approved protocol (MRC SCC 1436 and IMR IRB#1515 and
MRAC #16.14). Informed consent was obtained from all human participants. The
initial numbers of participants recruited for the Gambian cohort were based on
data outputs rather than formal power calculations. This effect size from the
Gambian dataset, however, allowed us to estimate the sample size needed for our
subsequently enrolled PNG validation cohort. Speciﬁcally, using the approach
described by Liu et al.30, the mean fold-change and standard deviation were esti-
mated in the Gambia transcriptomic data (using the data in Supplementary
Data 5–12), and, controlling the FDR at 5%, under different assumptions for the
proportion of non-DE features (0.8, 0.9), based on what was observed in the
Gambian cohort (~10% of transcripts DE at DOL3 and ~15% of transcripts DE at
DOL7), we estimated that with n= 10, we would have >80% power, even when
assuming a very low proportion of DE features (10%).
Following informed consent, mothers were screened for HIV-I and -II and
Hepatitis B with positivity for either virus representing an exclusion criterion.
Inclusion criteria were a healthy appearing infant as determined by physical
examination, born by vaginal delivery at gestational age of >36 weeks, 5-min Apgar
scores > 8, and a birth weight of >2.5 kilograms. Peripheral blood samples were
obtained from all infants on the day of birth (DOL0) and then again either at
DOL1, DOL3 or DOL7, in order to reduce venipuncture to a maximum of twice in
the ﬁrst week of life. Peripheral venous blood was drawn from infants via sterile
venipuncture directly into heparinized collection tubes (Becton Dickinson (BD)
Biosciences; San Jose, CA, USA). Aliquots (200 μl) were immediately placed in
RNA-later (Ambion ThermoFisher; Waltham, MA, USA) with the remaining
blood kept in the collection tubes at room temperature until further processing
within 4 h. All samples were processed as described below and subsequently
shipped to collaborating laboratories on dry ice, under temperature controlled and
monitored conditions (World Courier; New Hyde Park, NY, USA).
Indexing. The peripheral blood of each participant was proﬁled twice over their
ﬁrst week of life, i.e. at DOL0 and additionally at either DOL1, 3, or 7, as we sought
to identify variables that differed between the baseline and latter time points across
all participants. Obtaining a baseline DOL0 sample for each participant enabled
indexing as described in Methods. For univariate analyses, we considered (indexed)
paired differences implicitly using paired statistical tests (e.g. paired t test); for
multivariate analyses, participant sample pairing was addressed explicitly by
transforming the data beforehand using a multilevel approach to separate the
between- and within-subject variation31. We use the term indexing to refer to each
of these treatments, as appropriate, throughout the text.
While the limited number of samples available did not allow us to consider
additional potential confounders, such as when feeding started, ﬁrst passing of
meconium or birth weight, our approach of indexing data longitudinally for each
newborn allowed us to look for consistent differences between each DOL. While other
unforeseen confounders may exist, they did not obscure the strong developmental
patterns in the data observed during the ﬁrst week of life across two very different
cohorts.
Immune phenotyping. Whole blood was centrifuged on site at 500 × g for 10 min
at room temp and plasma harvested and stored at −80 °C for later analysis of
plasma cytokines, proteins and metabolites. The amount of plasma removed from
the whole blood after centrifugation was subsequently replaced with RPMI. For
assessment of cellular composition by FCM, ethylenediaminetetraacetic acid
(EDTA) (0.2 mM ﬁnal concentration) was added to the whole blood/RPMI mixture
to ensure adherent cells were not lost. In parallel, cells were stained with ﬁxable
viability dye at 4 °C for 15 min prior to red blood cell lysis followed by storage at
−80 °C in Smart Tube reagents (Smart Tube Inc.; San Carlos, CA, USA). At the
immunophenotyping laboratory samples were thawed, washed in staining buffer
(PBSAN; 0.5% bovine serum albumin (BSA), 0.1% sodium azide in PBS) and
stained on ice in PBSAN with a cocktail of anchor markers to determine frequency
of cell populations contained in peripheral blood (for list of cell types and anchor
markers, see Supplementary Figure 2; for list of clone/ ﬂuorochrome combination,
see Supplementary Note 1). Flow cytometric analysis employed a custom-built
LSRII (for machine settings and compensation settings, see Supplementary Note 1)
32. Our gating strategy is shown in Supplementary Figure 2. FCM data were
analyzed in an automated fashion using R/Bioconductor packages (Supplementary
Figure 2). Speciﬁcally, ﬂowCore supported the analysis in single ﬁles according to
the Flow Cytometry Standard (FCS), providing the infrastructure to support
subsetting of data, data transformations and gating33. Cell population identiﬁcation
was then conducted using ﬂowDensity, a supervised gating tool, that was custo-
mized to provide threshold calculations designed for each cell subset based on
expert knowledge of hierarchical gating order and one-dimensional density esti-
mation34. Lastly, ﬂowType/RchyOptimyx identiﬁed cell populations that correlated
with outcome, in this case DOL at the time of blood draw35. ﬂowType uses par-
titioning of cells, either manually or by clustering, into positive or negative for each
marker to enumerate all cell types in a sample. RchyOptimyx measures the
importance of these cell types by correlating their abundance to external outcomes,
such as DOL, and distills the identiﬁed phenotypes to their simplest possible form.
Plasma (25 μl) was used to measure cytokine concentrations using a custom-
designed multi-analyte Cytokine Human Magnetic Panel bead array, (Invitrogen/Life
Technologies; Carlsbad, CA) consisting of CCL2, CCL3, CCL5, CXCL8, CXCL10, GM-
CSF, IFN-a2, IL-10, IL-12p40, IL-12p70, IL-1β, IL-6, and TNFα. Results were obtained
with a Flexmap 3D system with Luminex xPONENT software version 4.2 (both from
Luminex Corp.; Austin, TX, USA). Cytokine concentrations were determined using
Milliplex Analyst software (version 3.5.5.0, Millipore).
For ﬂow cytometric as well as Luminex raw values were normalized with a 1+
Log2-transformation. WithinVariation matrices were computed for each data
matrix using the WithinVariation function in R package mixOmics version 6.1.2.
The Kruskal−Wallis test (kruska.test in base R) was used to determine
differentially regulated features within each data type, using the WithinVariation
values for each feature. These p values were adjusted for each data type separately
using the Benjamini−Hochberg method (p.adjust function, base R). Features were
considered statistically different by day of life from DOL0 if their adjusted p values
were below 0.05. All analyses were performed in R version 3.3.2 (2016-10-31).
RNA-Seq. Total RNA was extracted from each sample using the RiboPure RNA
puriﬁcation kit (Ambion ThermoFisher; Waltham, MA, USA) following the
manufacturer’s protocol. Quantiﬁcation and quality assessment of total RNA was
performed using an Agilent 2100 Bioanalyzer (Santa Clara, CA, USA). Poly-
adenylated RNA was captured using the NEBNext Poly(A) mRNA Magnetic
Isolation Module (catalog no.: E7409L, NEB; Ipswich, MA, USA). Strand-speciﬁc
cDNA libraries were generated from poly-adenylated RNA using the KAPA
Stranded RNA-Seq Library Preparation Kit (cat. no.: 07277253001, Roche; Basel,
Switzerland). All cDNA libraries were prepared at the same time and sequenced on
the HiSeq 2500 (Illumina; San Diego, CA, USA), using one Rapid v2 and two lanes
of High Output single-read run of 100 bp-long sequence reads (+ adapter/index
sequences). Sequence quality was assessed using FastQC v0.11.5 and MultiQC v0.8.
dev0 36. The FASTQ sequence reads were aligned to the hg38 human genome
(Ensembl GRCh38.86) using STAR v2.5 and mapped to Ensembl GRCh38 tran-
scripts37. Read-counts were generated using htseq-count (HTSeq 0.6.1p1)38. All
data processing and subsequent differential gene expression analyses were per-
formed using R version 3.3.0 and DESeq2 version 1.14.1 39. Genes with very low
counts (with less than ten counts in eight or more samples, or the smallest number
of biological replicates within each treatment group) and globin transcripts were
preﬁltered and removed in silico. Differentially expressed genes were identiﬁed
using paired analysis with the Wald statistics test and ﬁltering for any genes that
showed twofold change and adjusted p value < 0.05 (cut-off at 5% FDR) as the
threshold. Functional discovery of pathway enrichment and network analyses was
performed using SIGORA v2.0.1 and NetworkAnalyst, respectively17,40. To test
whether changes in cell composition could account for the observed changes in
gene expression, we used DESeq2 (with default parameters) to ﬁt two models, one
including subject and DOL and the other model including the additional covariate
of cell composition. To address the collinearity of this compositional data, we used
PCA, summarizing the cell proportions (ﬂow cytometry) to ﬁve principle com-
ponents (PCs, accounting for 95% of the variance observed). We compared the
estimated effect sizes for the DOL term between these two models (Pearson cor-
relation) across all genes and found them to be highly correlated (p < 10–50),
indicating that the observed changes in gene expression could not be (fully)
explained by changes in the underlying cell composition.
Plasma proteomics. Plasma samples were prepared for proteome analysis using
an in-house (Boston Children’s Hospital; Steen laboratory)-developed MStern
blotting sample processing and trypsinization protocol41, which was adapted for
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plasma samples42. To this end, 5 µl plasma was ﬁrst diluted in 100 µl sample
buffer (8 M urea in TRIS-HCl, pH 8.5). Protein disulﬁde bonds were then
reduced with dithiothreitol (10 mM ﬁnal concentration) for 30 min and alky-
lated with iodoacetamide (50 mM ﬁnal concentration) for 30 min in sample
buffer. Three µl (approximately 10 µg) of this protein solution was then trans-
ferred to a 96-well plate with a polyvinylidene ﬂuoride (PVDF) membrane at the
bottom. Protein digestion was performed with sequencing-grade modiﬁed
trypsin (V5111, Promega; Madison, WI, USA) at a nominal protease to protein
ratio of 1:25 w/w. After incubation for 2 h at 37 °C, the peptides were eluted from
the PVDF membrane, and concentrated to dryness in a vacuum centrifuge. To
monitor retention time stability and system performance, iRT peptides (Biog-
nosys; Schlieren, Switzerland) were spiked into all samples. Samples were ana-
lyzed using a nanoLC system (Eksigent; Dublin, CA) equipped with a LCchip
system (cHiPLC nanoﬂex, Eksigent) coupled online to a Q Exactive mass
spectrometer (Thermo Scientiﬁc; Bremen, Germany). From each sample, 0.2 µg
peptide material was separated using a linear gradient from 93% solvent A (0.1%
formic acid in water), 7% solvent B (0.1% formic acid in acetonitrile) which was
increased to 32% solvent B over 60 min. The mass spectrometer was operated in
data-dependent mode, selecting up to 12 of the most intense precursors for
fragmentation from each precursor scan. Label-free protein quantitation analysis
employed MaxQuant 1.5.3.30 43. Raw-data were downloaded and used to build a
matching library and searched against the UniProt Human Reference Proteome
as described. Standard search settings were employed with the following mod-
iﬁcations: Max missed cleavage 3; variable modiﬁcations Deamidation (NQ) and
Oxidation (M)44. A revert decoy search strategy was employed to ﬁlter all
proteins and peptides to <1% FDR. The list of proteins was further processed in
Perseus 1.5.5.3, log2-transformed, and proteins with less than two peptides
(razor) were ﬁltered out as described45. The samples were grouped according to
DOL, and proteins that were not quantiﬁable in at least ﬁve of the samples in any
day were ﬁltered out. Remaining missing values were imputed using numbers
drawn from a normal distribution with the standard parameters in Perseus
(width 0.3, downshift 1.8) to simulate signals from low abundant proteins The
R-script ComBat was used to correct for batch effects for samples run on dif-
ferent LC-MS columns46. Proteins with a statistically signiﬁcant change of
abundance between different DOL were identiﬁed by paired two-sample t test.
To correct for multiple hypothesis testing, permutation-based false positive
control was applied using standard parameters in Perseus (FDR= 0.05, s0= 0.1)
47. Signiﬁcant proteins were further analyzed using SIGORA40 with the Reac-
tome48 gene annotation system and DAVID49.
Plasma metabolomics. Plasma samples were run using the nontargeted metabo-
lomics platform of Metabolon Inc. (Durham, NC, USA). Samples were extracted
and prepared using Metabolon’s solvent extraction method50 and run on four
independent platforms: reverse-phase/UPLC-MS/MS with positive ion mode
electrospray ionization (ESI), reverse-phase/UPLC-MS/MS with negative ion mode
ESI, HILIC/UPLC-MS/MS with negative ion mode ESI, and a backup using Waters
ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo Sci-
entiﬁc Q-Exactive high resolution/accurate mass spectrometer interfaced with a
heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer
operated at 35,000 mass resolution. Biochemical identiﬁcations of metabolites
included the following three criteria: retention index (RI) within a narrow RI
window of the proposed identiﬁcation, accurate mass match to the library ± 10
ppm, and MS/MS forward and reverse scores between the experimental data and
authentic standards. The MS/MS scores were based on a comparison of the ions
present in the experimental spectrum to the ions present in the library spectrum.
Similarities between these molecules were based on one of these factors and the use
of all three data points can be utilized to distinguish and differentiate biochemicals.
The metabolites were conﬁrmed by comparing their mass spectra and chromato-
graphic retention times with more than 3300 commercially available reference
standards. All identiﬁed metabolites were categorized to level 1 metabolites
according to reporting standards set by the Chemical Analysis Working Group of
the Metabolomics Standards Initiative and have appropriate orthogonal analytical
techniques applied to the metabolite of interest and to a chemical reference stan-
dard. These identiﬁed metabolites included corresponding accurate mass via MS
with retention index, chemical and composition ID and accurate mass matched.
About 75% of the metabolites identiﬁed also have Pubchem ID associated with it.
MS/MS fragment ion analysis process was performed using peak-matching algo-
rithms (Waters MassLynx v4.1, Waters corp.; Milford, USA) and quantiﬁed using
an area-under-the-curve in-house algorithm. Metabolite features where all values
are missing/undetectable, features with a signal to noise ratio <10 and those with
just a single value in the whole dataset were excluded from the samples. All
remaining missing values were imputed with half the minimum value of peak
intensity for that feature. Features with interquartile range of zero were excluded to
ensure reproducibility. All metabolite features were then log-transformed for
normalization, pareto-scaled to reduce variation in fold change differences and for
robust size effect comparability across samples. Signiﬁcant metabolite between
DOL were identiﬁed using t test between paired samples corrected for multiple
hypothesis testing (threshold of adjusted p value < 0.05) using MetaboAnalyst 4.0.
Hypergeometric test enrichment of metabolite sets were matched against KEGG
Pathway51, The Human Metabolome Database Version 3.6 (HMDB)52 and
Metabolync Pathway Analysis using the Cytoscape plugin53.
Data integration. Data obtained via the immune phenotyping (cellular composition
and plasma cytokines), transcriptomic, proteomic and metabolomic methods was
integrated to identify correlations of signatures across these methodologically- and
biologically distinct datasets, since convergence of signatures across such diverse
biological domains provides an independent assessment and approaches functional
validation7. In addition, we assessed whether we could derive any novel biological
information via the integration of multiple OMICS data types that was not revealed in
a single dataset alone. To cross-validate results we employed three data integration
platforms, each applying a different analytical strategy; these independent but com-
plementary data-driven vs. knowledge/network-driven strategies, pursued in parallel,
decreased the chance of false discoveries. Speciﬁcally, data integration strategies
included: (i) a novel method for integrating multiple OMICS data types into known
protein−protein interaction networks (Molecular Interaction Network) using Net-
workAnalyst that provided context based on annotated molecular interactions17; (ii) a
new approach to identify the underlying key drivers of ontogeny using specialized
multivariate methods capable of identifying relevant features from high-dimensional
datasets, namely sparse generalized canonical correlation discriminant analysis via the
Data Integration Analysis for Biomarker discovery using Latent cOmponent (DIA-
BLO) framework, which is part of the mixOmics R package;18,19,54 and (iii) the
recently published MMRN, querying the informatically derived correlations within a
network for statistically signiﬁcant features7.
Molecular Interaction Network. NetworkAnalyst integrates data using protein
−protein interactions as a biological framework. Metabolomic data required pre-
processing in order to integrate into a network with transcriptomic and proteomic
data, as metabolites must be associated with proteins that are involved in their
creation and/or degradation. To identify such proteins, the following steps were
taken: metabolites were mapped to their directly interacting enzymes based on
their corresponding HMDB IDs via the MetaCyc module in MetaBridge55,56. To
construct networks for each OMICS type, the list of proteins derived from the
metabolite data processing (above), and lists of differentially expressed genes or
proteins identiﬁed by transcriptomic and proteomic data were submitted to Net-
workAnalyst to produce a zero-order or a minimum-connected network,
depending on the size of the dataset17. Networks consist of seed nodes (proteins/
genes that were used as input to build the network) and edges (links that join the
nodes together and are indicative of a molecular interaction between nodes).
Minimum-connected integrated networks were constructed using pairwise or
all three OMICS lists of differentially present genes/proteins on each later DOL vs.
DOL0 for transcriptomic, proteomic and metabolomic data. Novel nodes in each
network were identiﬁed as nodes that were not in either set of differentially
expressed genes/proteins nor found in minimum-connected networks constructed
from each single data type. Our focus was on the identiﬁcation of novel nodes as
emergent information that can be derived from a biological network. Node lists
were then downloaded to identify median degree of connectivity for nodes of each
data type and to identify novel nodes stemming from data integration.
Transcriptomes were integrated via their respective encoded gene products.
Pathway enrichment analysis was performed using SIGORA R package40 with the
Reactome ontology system on the node lists from each minimum-connected
network built during the novel node identiﬁcation process outlined above. For each
data type alone (transcriptomics, proteomics and metabolomics), the number of
unique pathways identiﬁed were counted as novel pathways. For each pairwise
combination of data types, previously identiﬁed pathways that had been identiﬁed
in either data type alone were subtracted. For the three-way combination all unique
data type pathways were subtracted.
DIABLO. Prior to integration with DIABLO, data were transformed. Speciﬁcally,
cell proportions from the ﬂow cytometry were normalized to total cell counts; the
resulting relative cell proportions were then transformed using centered log-
ratios57. Normalized transcriptomic, proteomic, cytokine, and metabolomic data
were log-transformed. We further decomposed the within-subject from the
between-subject variance in the datasets to account for repeated measures58. This is
analogous to normalizing all samples to their DOL0 time point. Finally, a broad,
unsupervised, variance-based ﬁlter was applied to the transcriptomic data,
retaining the 50% most variable features, also termed markers in the text. To
integrate across data types, we applied sparse generalized canonical correlation
discriminant analysis via the DIABLO framework, part of the mixOmics pack-
age18,19,59. DIABLO constructs components across any number of input matrices,
maximizing their covariance with each other and a given response variable (in this
case, DOL), while simultaneously performing feature selection23. Importantly,
DIABLO identiﬁes key drivers associated with the response variable of interest
across all input data matrices jointly. Cross-validation (20 × 5-fold) was used to
determine the optimal model hyperparameters (number of components, number of
features per component), as well as to provide an estimate of the ability of the
model to generalize to new data. Selected model features, i.e. key correlates of
change across DOL, were subjected to pathway over-representation analysis against
the Reactome pathways database (obtained via MSigDB60) and BTM21 annotated
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gene set libraries, using the hypergeometric test, either separately per component,
or after enrichment to include their ﬁrst-degree neighbors subgraph in the protein
−protein interaction data17. Obtained p values were adjusted for multiple com-
parisons using the Benjamini−Hochberg procedure61.
Multiscale, multifactorial response network. Examples of systematic integration
across multiple large OMICS datasets remain rare. Recently, Li et al.7 used MMRNs
to study the immune response to varicella zoster vaccine across four OMICS
datasets. We wanted to compare insights generated by our chosen approaches to
theirs and, to that end, created a multiscale interaction network as they described,
with the following important modiﬁcations. First, instead of summarizing the
higher dimensional data blocks (transcriptomics, metabolomics) to either gene
modules or metabolic pathways ((BTM)62; Metabolon Inc. annotation, respec-
tively) using a simple average, we used Eigen-gene summarization63, a weighted
average based on the ﬁrst principal component of the data, in order to maximize
the variance explained. Second, clusters were identiﬁed at each DOL using Eucli-
dean distance and Ward’s method as described64. The optimal number of clusters
was determined using the elbow criterion65. Stable clusters were identiﬁed by
comparing cluster membership using the Szymkiewicz−Simpson coefﬁcient66.
Finally, cluster association with DOL was assessed using the Correlation Adjusted
MEan RAnk (Camera) gene set test67.
Meta-integration to identify convergence across data integration strategies.
We performed meta-integration to address whether: (1) DIABLO-selected features
formed a functional network as deﬁned by known protein−protein interactions,
and (2) if each of the integration methodology, namely the Molecular Interaction
Networks integration, DIABLO and MMRN, would identify similar biological
signals across the ﬁrst week of life. To assess whether DIABLO-selected features
formed a functional protein−protein interaction network, 20 features each from
transcriptome, proteome, and metabolome data were used to create a minimum-
connected network. Metabolites were mapped to their directly interacting enzymes
based on their corresponding HMDB IDs via the MetaCyc module in Meta-
Bridge55,56 as above, and used as seed nodes for NetworkAnalyst.
The various data integration approaches resulted in outputs that were not
directly comparable. To enable direct comparisons, we simpliﬁed their outputs to
lists of features of interest. Molecular Interaction Networks integration: list of
features that made up a minimum-connected network using nodes from
differentially abundant features (transcripts, proteins and metabolites) for DOL3
vs. DOL0 and DOL7 vs. DOL0 (3195 features). DIABLO: a ﬁrst-order connected
network including seed nodes of component 1 and 2 features of the DIABLO
model using NetworkAnalyst (428 features). MMRN: features were selected from
the small stable interconnected node-network of transcriptomic and metabolomics
features shown in Supplementary Figure 7 (675 features). Pathway enrichment of
3195 (Molecular Interaction Networks integration), 428 (DIABLO) and 675
features (MMRN) was done using ReactomePA with the Reactome annotation and
the comparison of enriched pathways was performed using clusterProﬁler68,69.
Data availability
All data are publicly available. The transcriptomics data presented in this publication
were submitted to the NCBI Gene Expression Omnibus under accession numbers
GSE111404 and GSE123070. All other datasets including immune phenotyping, Lumi-
nex, metabolomics and proteomics data were archived on ImmPort (https://immport.
niaid.nih.gov/home) under accession numbers SDY1256 and SDY1412.
Received: 18 February 2018 Accepted: 24 January 2019
References
1. Kollmann, T. R., Kampmann, B., Mazmanian, S. K., Marchant, A. & Levy, O.
Protecting the newborn and young infant from infectious diseases: lessons
from immune ontogeny. Immunity 46, 350–363 (2017).
2. Balbus, J. M. et al. Early-life prevention of non-communicable diseases. Lancet
381, 3–4 (2013).
3. Chaussabel, D. & Pulendran, B. A vision and a prescription for big data-
enabled medicine. Nat. Immunol. 16, 435–439 (2015).
4. Olin, A. et al. Stereotypic immune system development in newborn children.
Cell 174, 1277–1292 (2018).
5. Jennewein, M. F., Butler, A. L. & Alter, G. Neonate-omics: charting the
unknown immune response in early life. Cell 174, 1051–1053 (2018).
6. Amenyogbe, N., Levy, O. & Kollmann, T. R. Systems vaccinology: a promise
for the young and the poor. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370,
20140340 (2015).
7. Li, S. et al. Metabolic phenotypes of response to vaccination in humans. Cell
169, 862–877 (2017).
8. Howie, S. R. Blood sample volumes in child health research: review of safe
limits. Bull. World Health Organ. 89, 46–53 (2011).
9. Tsang, J. S. Utilizing population variation, vaccination, and systems biology to
study human immunology. Trends Immunol. 36, 479–493 (2015).
10. Carr, E. J. et al. The cellular composition of the human immune system is
shaped by age and cohabitation. Nat. Immunol. 17, 461–468 (2016).
11. Smolen, K. K. et al. Single-cell analysis of innate cytokine responses to pattern
recognition receptor stimulation in children across four continents. J.
Immunol. 193, 3003–3012 (2014).
12. Tsang, J. S. et al. Global analyses of human immune variation reveal baseline
predictors of postvaccination responses. Cell 157, 499–513 (2014).
13. Shannon, C. P. et al. Two-stage, in silico deconvolution of the lymphocyte
compartment of the peripheral whole blood transcriptome in the context of
acute kidney allograft rejection. PLoS ONE 9, e95224 (2014).
14. Smith, C. L. et al. Identiﬁcation of a human neonatal immune-metabolic
network associated with bacterial infection. Nat. Commun. 5, 4649 (2014).
15. Henry, E. & Christensen, R. D. Reference intervals in neonatal hematology.
Clin. Perinatol. 42, 483–497 (2015).
16. McCallie, K. R. et al. Skin-to-skin contact after birth and the natural course of
neurosteroid levels in healthy term newborns. J. Perinatol. 37, 591–595
(2017).
17. Xia, J., Gill, E. E. & Hancock, R. E. NetworkAnalyst for statistical, visual and
network-based meta-analysis of gene expression data. Nat. Protoc. 10,
823–844 (2015).
18. Le Cao, K. A., Boitard, S. & Besse, P. Sparse PLS discriminant analysis:
biologically relevant feature selection and graphical displays for multiclass
problems. BMC Bioinforma. 12, 253 (2011).
19. Singh, A. et al. DIABLO—an integrative, multi-omics, multivariate method for
multi-group classiﬁcation. Preprint at https://www.biorxiv.org/content/
10.1101/067611v2. (2018).
20. Rohart, F., Gautier, B., Singh, A. & Le Cao, K. A. mixOmics: an R package for
‘omics feature selection and multiple data integration. PLoS Comput. Biol. 13,
e1005752 (2017).
21. Chaussabel, D. & Baldwin, N. Democratizing systems immunology with
modular transcriptional repertoire analyses. Nat. Rev. Immunol. 14, 271–280
(2014).
22. Breuer, K. et al. InnateDB: systems biology of innate immunity and beyond--
recent updates and continuing curation. Nucleic Acids Res. 41, D1228–D1233
(2013).
23. Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc.
B (Methodol.) 58, 267–288 (1996).
24. Ismail, A. A., Walker, P. L., Macfaul, R. & Gindal, B. Diagnostic value of
serum testosterone measurement in infancy: two case reports. Ann. Clin.
Biochem. 26(Pt 3), 259–261 (1989).
25. Romero-Moya, D. et al. Cord blood-derived CD34+hematopoietic cells with
low mitochondrial mass are enriched in hematopoietic repopulating stem cell
function. Haematologica 98, 1022–1029 (2013).
26. Lugo, B., Ford, H. R. & Grishin, A. Molecular signaling in necrotizing
enterocolitis: regulation of intestinal COX-2 expression. J. Pediatr. Surg. 42,
1165–1171 (2007).
27. Reinebrant, H. E. et al. Cyclo-oxygenase (COX) inhibitors for treating preterm
labour. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.
CD001992.pub3 (2015).
28. Fan, J. & Lv, J. A selective overview of variable selection in high dimensional
feature space. Stat. Sin. 20, 101–148 (2010).
29. Bennike, T. B. et al. A cost-effective high-throughput plasma and serum
proteomics workﬂow enables mapping of the molecular impact of total
pancreatectomy with islet autotransplantation. J. Proteome Res. 17, 1983–1992
(2018).
30. Liu, P. & Hwang, J. T. Quick calculation for sample size while controlling false
discovery rate with application to microarray analysis. Bioinformatics 23,
739–746 (2007).
31. Westerhuis, J. A., van Velzen, E. J., Hoefsloot, H. C. & Smilde, A. K.
Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metab.:
Off. J. Metab. Soc. 6, 119–128 (2010).
32. Lee, J. A. et al. MIFlowCyt: the minimum information about a Flow
Cytometry Experiment. Cytometry 73, 926–930 (2008).
33. Hahne, F. et al. ﬂowCore: a Bioconductor package for high throughput ﬂow
cytometry. BMC Bioinforma. 10, 106 (2009).
34. Malek, M. et al. ﬂowDensity: reproducing manual gating of ﬂow cytometry
data by automated density-based cell population identiﬁcation. Bioinformatics
31, 606–607 (2015).
35. O’Neill, K., Jalali, A., Aghaeepour, N., Hoos, H. & Brinkman, R. R. Enhanced
ﬂowType/RchyOptimyx: a BioConductor pipeline for discovery in high-
dimensional cytometry data. Bioinformatics 30, 1329–1330 (2014).
36. Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize
analysis results for multiple tools and samples in a single report.
Bioinformatics 32, 3047–3048 (2016).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08794-x
12 NATURE COMMUNICATIONS |         (2019) 10:1092 | https://doi.org/10.1038/s41467-019-08794-x | www.nature.com/naturecommunications
37. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29,
15–21 (2013).
38. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work
with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
39. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change
and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550
(2014).
40. Foroushani, A. B., Brinkman, F. S. & Lynn, D. J. Pathway-GPS and SIGORA:
identifying relevant pathways based on the over-representation of their gene-
pair signatures. PeerJ 1, e229 (2013).
41. Berger, S. T. et al. MStern blotting-high throughput polyvinylidene ﬂuoride
(PVDF) membrane-based proteomic sample preparation for 96-well plates.
Mol. Cell. Proteom. 14, 2814–2823 (2015).
42. Bennike, T. B. & Steen, H. High-throughput parallel proteomic sample
preparation using 96-well polyvinylidene ﬂuoride (PVDF) membranes and
C18 puriﬁcation plates. Methods Mol. Biol. 1619, 395–402 (2017).
43. Cox, J. et al. Accurate proteome-wide label-free quantiﬁcation by delayed
normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol.
Cell. Proteom. 13, 2513–2526 (2014).
44. Bennike, T. et al. A normative study of the synovial ﬂuid proteome from
healthy porcine knee joints. J. Proteome Res. 13, 4377–4387 (2014).
45. Bennike, T. B. et al. Proteome analysis of rheumatoid arthritis gut mucosa. J.
Proteome Res. 16, 346–354 (2017).
46. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 8, 118–127 (2007).
47. Camargo, A., Azuaje, F., Wang, H. & Zheng, H. Permutation-based statistical
tests for multiple hypotheses. Source Code Biol. Med. 3, 15 (2008).
48. Croft, D. et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 42,
D472–D477 (2014).
49. Shannon, P. et al. Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
50. Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M. & Milgram, E.
Integrated, nontargeted ultrahigh performance liquid chromatography/
electrospray ionization tandem mass spectrometry platform for the
identiﬁcation and relative quantiﬁcation of the small-molecule complement of
biological systems. Anal. Chem. 81, 6656–6667 (2009).
51. Ogata, H., Goto, S., Fujibuchi, W. & Kanehisa, M. Computation with the
KEGG pathway database. Biosystems 47, 119–128 (1998).
52. Wishart, D. S. et al. HMDB 3.0—The Human Metabolome Database in 2013.
Nucleic Acids Res. 41, D801–D807 (2013).
53. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8:
new features for data integration and network visualization. Bioinformatics 27,
431–432 (2011).
54. Rohart, F., Gautier, B., Singh, A. & Le Cao, K.-A. mixOmics: an R package for
‘omics feature selection and multiple data integration. Preprint at https://doi.
org/10.1101/108597 (2017).
55. Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes and
the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res. 42,
D459–D471 (2014).
56. Hinshaw, S. J., Lee, A. H. Y., Gill, E. E. & Hancock, R. E. W. MetaBridge:
enabling network-based integrative analysis via direct protein interactors of
metabolites. Bioinformtics 34, 3225–3227 (2018).
57. Aitchison, J. The statistical analysis of compositional data. J. R. Stat. Soc. B
(Methodol.) 44, 139–177 (1982).
58. Liquet, B., Le Cao, K. A., Hocini, H. & Thiebaut, R. A novel approach for
biomarker selection and the integration of repeated measures experiments
from two assays. BMC Bioinforma. 13, 325 (2012).
59. Singh, A. et al. Identifying molecular mechanisms of the late-phase asthmatic
response by integrating cellular, gene, and metabolite levels in blood. Ann.
Am. Thorac. Soc. 13(Suppl 1), S98 (2016).
60. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression proﬁles. Proc. Natl Acad.
Sci. USA 102, 15545–15550 (2005).
61. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J. R. Stat. Soc. B (Methodol.) 57,
289–300 (1995).
62. Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S. & Presnell, S.
Molecularsignatures of antibody responses derived from a systems biology
study of ﬁvehuman vaccines. Nat. Immunol. 15, 195–204 (2014).
63. Langfelder, P. & Horvath, S. Eigengene networks for studying the relationships
between co-expression modules. Bmc Syst. Biol. 1, 54 (2007).
64. Ward, J. H. Hierarchical grouping to optimize an objective function. J. Am.
Stat. Assoc. 58, 236–244 (1963).
65. Thorndike, R. L. Who belongs in the family? Psychometrika 18, 267–276
(1953).
66. Shannon, C. P. et al. SABRE: a method for assessing the stability of gene
modules in complex tissues and subject populations. BMC Bioinforma. 17, 460
(2016).
67. Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for
inter-gene correlation. Nucleic Acids Res. 40, e133 (2012).
68. Yu, G. & He, Q. Y. ReactomePA: an R/Bioconductor package for reactome
pathway analysis and visualization. Mol. Biosyst. 12, 477–479
(2016).
69. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProﬁler: an R package for
comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).
Acknowledgements
We would like to thank all the participants and their parents for their time and will-
ingness to support this study. Research reported in this publication was supported by the
National Institute of Allergy and Infectious Diseases of the National Institutes of Health
as part of the Human Immunology Project consortium under 5U19AI118608-02. The
content is solely the responsibility of the authors and does not necessarily represent the
ofﬁcial views of the National Institutes of Health. T.R.K.’s laboratory is supported by a
Michael Smith Foundation for Health Research Career Investigator Award. O.L.’s
laboratory is supported by the following U.S. National Institutes of Health (NIH)/
National Institutes of Allergy and Infectious Diseases (NIAID) awards: Molecular
Mechanisms of Combination Adjuvants (1U01AI124284-01), Adjuvant Discovery Pro-
gram Contract No. HHSN272201400052C and Human Immunology Project Consortium
(U19AI118608) as well as an internal Boston Children’s Hospital award to the Precision
Vaccines Program. B.K. is supported by grants from the MRC/UKRI (MC_UP_A900/
1122, MC_UP_A900/115, MR/R005990/1), and the additional ﬁeld team and laboratory
staff at the MRC Unit in The Gambia. Recruitment of the cohort of newborns in Papua
New Guinea was funded by seed funding awarded to A.H.J.v.d.B from the Wesfarmers
Centre of Vaccines and Infectious Diseases, Telethon Kids Institute. The work in R.E.W.
H.’s lab was initially supported by the Canadian Institutes for Health Research grant #
FDN-154287 and he holds a Canada Research Chair in Health and Genomics and a UBC
Killam Professorship. R.R.B.’s laboratory is supported by an award from Natural Sciences
and Engineering Research Council of Canada. The Lundbeck Foundation (R181-2014-
3372), The Carlsberg Foundation (CF14-0561), and A.P. Møller Foundation are
acknowledged for grants enabling T.B.B.’s work. K.-A.L.C. is supported in part by the
National Health and Medical Research Council (NHMRC) Career Development fel-
lowship (GNT1087415). We gratefully acknowledge the support from Drs. Gary Fleisher,
Michael Wessels and Ken Kraft as well as Maria Crenshaw, Mark Liu, Kerry McEnaney
and Diana Vo (all BCH); Susan Farmer, Manish Sadarangani, Aaron Liu, Gordean
Bjornson (all UBC). The Expanded Program on Immunization Consortium (EPIC)
contributed collectively to this study. EPIC is an association of academic centers part-
nering to conduct systems biology studies in newborns and infants, comprised of the
investigators listed above at Boston Children’s Hospital (BCH), University of British
Columbia (UBC), Medical Research Council Unit The Gambia (MRCG), Université libre
de Bruxelles, Telethon Kids Institute and University of Western Australia, and the Papua
New Guinea Institute for Medical Research (PNG-IMR).
Author contributions
Project and core leads were: O.L., T.R.K., H.S., R.E.W.H., S.J.T., A.O., A.H.J.v.d.B., and B.
K. Project activities were coordinated by the Administrative Core (O.L., J.D.-A., D.V., K.
K.S; BCH; T.R.K., R.B.-O.; UBC). All infants were enrolled at the MRCG (O.I., B.K.) and
PNG-IMR (W.S.P., A.H.J.v.d.B.), where biospecimens were collected, processed and
shipped (M.C., A.D., J.N.-J., J.N., E.R., R.F., G.S., G.M., J.P.M., W.K.), to the Clinical Core
(K.K.S., O.L., S.v.H.; BCH) for further processing. Data generation and analyses were
conducted at centers specializing in RNASeq (A.H.L., E.E.G., R.F., R.E.W.H.; UBC),
proteomics (T.B.B., H.S.; BCH), cytokine/chemokine analysis (S.v.H, O.L.; BCH; N.A.; D.
H.; UBC), ﬂow cytometry (T.R.K., N.A., R.B.-O., C.B., D.J.H.; M.M., R.R.B.; UBC), with
metabolomics data provided to O.L. and J.D.-A. (BCH) on a fee-for service basis
(Metabolon; Durham, NC). Data underwent QC and QA and were released via the Data
Management Core (J.D.-A., S.M.V., K.M., A.O.; BCH; C.P.S., S.J.T.; UBC & PROOF
Centre; R.E.W.H., R.B.-O.; UBC). Writing team: A.H.L., C.P.S., R.B.-O., N.A., T.B.B., J.
D.-A., O.L., and T.R.K.; development of the clinical protocol: A.H.J.v.d.B., B.K., O.I., O.L.,
T.R.K., P.C.R., and W.S.P.; development of the protocol for fractionating small blood
samples: G.S.-S., M.A.P., N.A., O.L., R.B.-O., S.v.H., and T.R.K., for RNASeq: A.H.L., E.E.
G., R.E.W.H.; proteomics: T.B.B., H.S.; metabolomics: J.D.-A., M.A.P.; ﬂow cytometry
and automated ﬂow data analyses: R.B.-O., D.H., D.J.H., R.R.B., M.M., T.R.K., cytokine/
chemokine multiplexing: S.v.H.; data integration: C.P.S., E.E.G., J.D.-A., A.H.L., S.J.H., A.
S., S.J.T., and R.E.W.H. K.-A.L.C. and D.F. contributed to the conceptualization and
writing of the bioinformatic analyses. A.A. assisted in interpretation of neonatal mole-
cular ontogeny. A.M. assisted with study design. K.K. provided expert input on opti-
mizing the structure and function of the EPIC organization. S.M.V. served as the
Precision Vaccines Program Data Coordinator for deposition of deidentiﬁed study data
to NIH’s ImmPort and Gene Expression Omnibus (GEO) public repository website. D.V.
provide project coordination via the Precision Vaccines Program. All authors reviewed
and approved the ﬁnal version of the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-08794-x.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08794-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1092 | https://doi.org/10.1038/s41467-019-08794-x | www.nature.com/naturecommunications 13
Competing interests: O.L. is a named inventor on patents regarding bactericidal/
permeability increasing protein (BPI), including “Therapeutic uses of BPI protein
products in BPI-deﬁcient humans” (WO2000059531A3) and “BPI and its congeners as
radiation mitigators and radiation protectors” (WO2012138839A1). R.R.B. has
ownership interest in Cytapex Bioinformatics Inc. The remaining authors declare no
competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks the anonymous
reviewers for their contribution to the peer review of this work. Peer reviewer reports are
available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
1
Department of Microbiology & Immunology, University of British Columbia, 1365-2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.
2PROOF Centre of Excellence, 10th Floor, 1190 Hornby Street, Vancouver, BC V6Z 2K5, Canada. 3Department of Experimental Medicine,
University of British Columbia, 2775 Laurel Street, 10th Floor, Room 10117, Vancouver, BC V5Z 1M9, Canada. 4Department of Pathology, Boston
Children’s Hospital, BCH 3108, 300 Longwood Ave, Boston, MA 02115, USA. 5Precision Vaccines Program, Division of Infectious Diseases,
Boston Children’s Hospital, 300 Longwood Ave, BCH 3104, Boston, MA 02115, USA. 6Harvard Medical School, 25 Shattuck Street, Boston, MA
02115, USA. 7Vaccines & Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine,
Atlantic Boulevard P.O. Box 273 Banjul, Gambia. 8Center for International Health, Medical Center of the University of Munich (LMU), Munich,
Germany. 9Department of Pediatrics, BC Children’s Hospital, University of British Columbia, Rm 2D19, 4480 Oak Street, Vancouver, BC V6H
3V4, Canada. 10Papua New Guinea Institute of Medical Research, Homate Street, Goroka, Eastern Highlands Province, Papua New Guinea.
11Statistical Genomics, School of Mathematics and Statistics, Melbourne Integrative Genomics, Centre for Systems Genomics, The University of
Melbourne, Building 184 Ground Floor, Parkville, VIC 3010, Australia. 12Graduate Program in Bioinformatics, BCCA, 100−570 West 7th Avenue,
Vancouver, BC V5Z 4S6, Canada. 13Division of Paediatrics, School of Medicine, University of Western Australia, 35 Stirling Highway, Nedlands,
WA 6009, Australia. 14Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia Perth, 15
Hospital Avenue, Nedlands, WA 6009, Australia. 15BC Cancer Agency, 686 West Broadway, Suite 500, Vancouver, BC V5Z 1G1, Canada.
16Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Rm. G227–2211 Wesbrook Mall,
Vancouver, BC V6T 2B5, Canada. 17Division of Newborn Medicine, Boston Children’s Hospital, 300 Longwood Ave, BCH 3146, Boston, MA 02115,
USA. 18Department of Medical Genetics, University of British Columbia, Vancouver V6T1Z4 BC, Canada. 19Center for Applied Pediatric Quality
Analytics, Boston Children’s Hospital, Boston 02115 MA, USA. 20UBC Centre for Heart and Lung Innovation, Vancouver V6T1Z4 BC, Canada.
21Department of Medicine, Division of Respiratory Medicine, UBC, Vancouver V6T1Z4 BC, Canada. 22The Vaccine Centre, Faculty of Infectious
and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. 23Broad Institute of MIT & Harvard, Cambridge
02142 MA, USA. 24Institute for Medical Immunology, Universite ́ libre de Bruxelles, Charleroi, Rue Adrienne Bolland 8, 6041 Gosselies, Belgium.
25Present address: Telethon Kids Institute, 100 Roberts Road, Subiaco 6008, Australia. 26Present address: Department of Health Science and
Technology, Aalborg University, Fredrik Bajers Vej 7 D2, 9220 Aalborg, Denmark. 27Present address: Department of Pathology, Anatomy and Cell
Biology, Thomas Jefferson University, Jefferson Alumni Hall, 1020 Locust Street, Suite 279, Philadelphia, PA 19107, USA. These authors
contributed equally: Amy H. Lee, Casey P. Shannon, Nelly Amenyogbe, Tue B. Bennike, Joann Diray-Arce, Olubukola Idoko. These authors jointly
supervised this work: Anita H. J. van den Biggelaar, Hanno Steen, Scott J. Tebbutt, Beate Kampmann, Ofer Levy, Tobias R. Kollmann.
The EPIC Consortium
Diana Vo5, Ken Kraft5,6, Kerry McEnaney5,18, Soﬁa Vignolo5 & Arnaud Marchant24
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08794-x
14 NATURE COMMUNICATIONS |         (2019) 10:1092 | https://doi.org/10.1038/s41467-019-08794-x | www.nature.com/naturecommunications
